Preventing Adverse Drug Events With PatientSite
18 Years
N/A
Both
Adverse Drug Event
Trial Information
Preventing Adverse Drug Events With PatientSite
- A drug safety module called MedCheck was developed for PatientSite. This allows
physicians to query patients automatically 10 days after they receive a new
prescription asking them questions about their new prescription. In this study new
enhancements will be tested.
- Participants will be assigned at random to the intervention group or control group.
The intervention group will receive a single electronic PatientSite message asking them
questions about the new prescription which is then forwarded to their physician. The
control group will receive a generic message about medication safety.
- To identify adverse drug events, a telephone survey and medical record review will be
conducted of patients in the intervention group and controls.
- This study will run for 12 months.
Inclusion Criteria:
- Adult patients >18
- Patients that receive a new prescription
- Proficient in spoken and written english
Exclusion Criteria:
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
Outcome Measure:
To prevent adverse drug events with PatientSite.
Outcome Time Frame:
3 years
Safety Issue:
No
Principal Investigator
Saul N Weingart, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Dana-Farber Cancer Institute
Authority:
United States: Institutional Review Board
Study ID:
05-061
NCT ID:
NCT00140504
Start Date:
April 2003
Completion Date:
December 2004
Related Keywords:
- Adverse Drug Event
- Adverse drug event
- Patient safety
- Internet portal
- PatientSite
- Preventive health
- Primary care
- Drug Toxicity
Name | Location |
|---|---|
| Beth Israel Deaconess Medical Center | Boston, Massachusetts 02215 |
